Approved October 1997
Psychiatry / Psychiatric
Sano's generic transdermal nicotine patch, the equivalent of Novartis' Habitrol, has been approved for marketing.
Health risks from smoking cigarettes are widely recognized. Although most smokers say they would like to quit, more than 50 million Americans continue to smoke. A 1990 Journal of the National Cancer Institute study found that nearly 90% of smokers have attempted to quit at some point, but fewer than 10 percent achieve long-term success.
The Generic Transdermal Nicotine Patch drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.